Survodutide induces ‘impressive’ weight loss in type 2 diabetes
Healio reports results from the phase 3 SYNCHRONIZE-2 trial of survodutide, a once-weekly injectable GLP-1/glucagon dual agonist, in 752 adults with type 2 diabetes and overweight or obesity. At 76 weeks, weight fell 8.2% and 9.8% on the 3.6 mg and 6 mg doses versus 3.9% with placebo. Gastrointestinal side effects were common and led some participants to stop treatment. The trial was funded by Boehringer Ingelheim.
Why it matters: Relevant to Maryland adults with type 2 diabetes and overweight or obesity exploring medical weight loss, and to the clinicians who refer them.
A summary of another publisher's reporting, written with AI and checked automatically against the story. The reporting belongs to healio.com. October 3, 2026.